LVEF stands for left ventricular ejection fraction, and it measures how well the main pumping chamber of your heart pushes blood out with each beat. Expressed as a percentage, it tells cardiologists what fraction of the blood sitting in that chamber actually gets ejected into the body. A normal LVEF falls between about 55% and 70%, and it’s one of the most commonly ordered measurements in heart disease evaluation.
How LVEF Is Calculated
Your left ventricle fills with blood between heartbeats, reaching what’s called the end-diastolic volume. When the heart contracts, it squeezes out a portion of that blood but not all of it. The amount left behind is the end-systolic volume. LVEF is simply the difference between those two numbers divided by the starting volume, then expressed as a percentage.
So if your left ventricle holds 120 mL of blood when full and 50 mL remains after it contracts, the stroke volume is 70 mL. Dividing 70 by 120 gives you an ejection fraction of about 58%. That single number captures, in a rough but useful way, how effectively your heart muscle is contracting.
What the Numbers Mean
Cardiologists use specific LVEF cutoffs to classify heart failure into three categories, based on guidelines from the American College of Cardiology:
- 50% or higher: Heart failure with preserved ejection fraction (HFpEF). The heart squeezes normally, but other problems, often related to stiffness or relaxation, cause symptoms.
- 41% to 49%: Heart failure with mildly reduced ejection fraction (HFmrEF). This was previously called “mid-range” and sits in a gray zone where treatment decisions are less clear-cut.
- 40% or below: Heart failure with reduced ejection fraction (HFrEF). The heart muscle is significantly weakened and can’t pump enough blood to meet the body’s demands.
These categories matter because they determine which treatments are most effective. An LVEF below 40% is widely considered the threshold for a clearly weakened heart and triggers a specific set of medication and device recommendations.
How LVEF Is Measured
The most common way to measure LVEF is an echocardiogram, an ultrasound of the heart. It’s noninvasive, widely available, and doesn’t expose you to radiation. The European Society of Cardiology recommends echocardiography as the first-line tool for monitoring LVEF over time. Three-dimensional echocardiography is preferred when available because it captures the full shape of the left ventricle rather than relying on geometric assumptions, which makes it more accurate and reproducible.
Cardiac MRI is considered the gold standard for measuring ventricular volumes and function. It produces the clearest and most reliable images of the heart chambers. However, it’s more expensive, takes longer, and isn’t always practical for routine follow-up. A third option, the MUGA scan (a nuclear imaging test), offers highly reproducible results but involves radiation exposure and can’t evaluate structural problems beyond the ejection fraction itself.
These methods don’t always agree perfectly. Research comparing imaging techniques has found that MUGA and cardiac MRI should not be used interchangeably because they can produce meaningfully different LVEF values for the same patient. This becomes especially important near decision-making thresholds, like the 35% cutoff used for device implantation, where a few percentage points can change the treatment plan entirely.
Symptoms of a Low Ejection Fraction
When LVEF drops significantly, the heart can’t deliver enough blood to keep up with your body’s needs. Blood backs up behind the weakened pump, and fluid starts accumulating where it shouldn’t. The most common symptoms include shortness of breath (especially with activity or when lying flat), fatigue and general weakness, swelling in the legs, ankles, and feet, and a rapid or irregular heartbeat.
Fluid can also build up in the lungs, making it hard to breathe, or accumulate in the abdomen, causing bloating and discomfort. In more advanced cases, poor blood flow can make the skin look bluish or gray. These symptoms sometimes develop gradually over weeks or months, but they can also appear suddenly after an event like a heart attack.
Treatment Based on LVEF
For patients with reduced ejection fraction (40% or below), current guidelines call for four classes of medication working together. These include drugs that block the hormonal systems driving heart failure progression, beta blockers that slow the heart rate and reduce its workload, medications that counteract a hormone called aldosterone which causes fluid retention, and a newer class of drugs originally developed for diabetes that have shown clear benefits for the heart. Starting all four classes, sometimes called guideline-directed medical therapy, has become the standard approach because each one works through a different mechanism and the benefits stack.
For patients in the mildly reduced range (41% to 49%), the evidence is less robust, but several of these same drug classes carry moderate recommendations. For preserved ejection fraction (50% and above), treatment options have historically been limited, though newer medications, particularly the diabetes-related class, now carry recommendations for this group as well.
LVEF also determines eligibility for implanted devices. Patients whose ejection fraction remains at or below 35% despite optimal medication may qualify for an implantable defibrillator, which protects against dangerous heart rhythms. Some patients also benefit from a specialized pacemaker that coordinates the timing of the heart’s contractions to improve pumping efficiency.
Limitations of LVEF
Despite its central role in cardiology, LVEF has real shortcomings. Measurement reproducibility is poor, particularly with standard two-dimensional echocardiography. Different technicians scanning the same patient can get noticeably different numbers, and even the same technician can produce varying results on repeat scans. Age and sex differences in heart size also contribute to this variability.
Perhaps more importantly, LVEF loses its predictive power as it climbs above 45%. At higher values, the number doesn’t correlate well with how severe a patient’s heart dysfunction actually is or how they’ll do over time. Two patients with an LVEF of 55% can have dramatically different exercise tolerance and quality of life. This is part of why HFpEF has been so difficult to study and treat: the ejection fraction looks reassuring even when the heart isn’t functioning normally.
A 2024 clinical consensus statement from major heart failure societies in Europe, the United States, and Japan acknowledged these limitations directly, noting that LVEF’s diagnostic and prognostic value diminishes above 45% and that it shows no relationship with the severity of cardiac dysfunction or outcomes at higher values. For all its usefulness as a quick snapshot, LVEF is one piece of a larger clinical picture, not a definitive measure of heart health on its own.